Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
1.5
0.9
Journals
Gastrointestinal Disorders
Special Issues
Coeliac Disease 2.0
share announcement

Coeliac Disease 2.0

A special issue of Gastrointestinal Disorders (ISSN 2624-5647).

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 11661

Special Issue Editor

Prof. Dr. John Mayberry

E-Mail Website
Guest Editor
Department of Gastroenterology, Nuffield Hospital, Scraptoft Lane, Leicester LE5 5HY, UK
Interests: inflammatory bowel disease; coeliac disease; achalasia; screening; epidemiology; public health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There are a number of developments in coeliac disease which warrant a timely review. The major issues are: 1) The widening occurrence of the disease; 2) The new approaches to treatment, including new varieties of gluten-free wheat, drugs and vaccines; 3) The difficulties in complying with diet, with many issues related to the wider population base at risk; 4) The impact on fertility and mood; 5) The emergence of gluten sensivity without celiac disease.

This Special Issue on coeliac disease will accept basic research and pre-clinic research articles, case reports, case series or clinical image articles, short communications, and review articles. We welcome but are not limited to the following subtopics:

  • The changing face of coeliac disease;
  • Epidemiology of coeliac disease;
  • What triggers celiac disease and what can we do about it?
  • Coeliac disease in Punjabis and dietary implications;
  • Dietary issues for patients in the 21st century;
  • Lymphoma and other tumours;
  • Coeliac disease and inflammatory bowel disease;
  • Coeliac disease, fertility and obstetric issues;
  • Mood disorders in celiac disease;
  • Drugs or vaccines as a treatment?
  • Gluten sensitivity without celiac disease.

Prof. Dr. John Mayberry
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastrointestinal Disorders is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (8 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review, Other

4 pages, 376 KiB  
Editorial
Punjabis and Coeliac Disease: A Wake-Up Call
by Affifa Farrukh and John F. Mayberry
Gastrointest. Disord. 2020, 2(2), 171-174; https://doi.org/10.3390/gidisord2020018 - 17 Jun 2020
Cited by 3 | Viewed by 3351
Abstract
Punjabis are one of the largest ethnic groups in the world, with at least 124 million members. Their diet is based around wheat cereals and they are now recognised to be at risk of coeliac disease. Indeed, the incidence of coeliac disease amongst [...] Read more.
Punjabis are one of the largest ethnic groups in the world, with at least 124 million members. Their diet is based around wheat cereals and they are now recognised to be at risk of coeliac disease. Indeed, the incidence of coeliac disease amongst Punjabi migrants is three times that of other Europeans, suggesting that in excess of 3 million Punjabi people may be affected by the condition. This review considers the history of coeliac disease and its lack of ready diagnosis in the Punjabi community, including the adverse outcomes as a result. It considers the poor-quality information available to Punjabi patients and tentatively suggests methods of dealing with these issues. Full article
(This article belongs to the Special Issue Coeliac Disease)

Review

Jump to: Editorial, Other

8 pages, 277 KiB  
Review
Measurement of Pain and Related Symptoms in Irritable Bowel Syndrome: The Use of Validated Pain Measurement Tools
by Affifa Farrukh
Gastrointest. Disord. 2022, 4(1), 22-29; https://doi.org/10.3390/gidisord4010004 - 9 Feb 2022
Cited by 2 | Viewed by 11128
Abstract
This paper reviews the tools available to assess outcomes of treatment in irritable bowel syndrome, especially the effect on abdominal pain. Tools were identified through a wide-ranging scrutiny of PubMed and Google Scholar, together with a review of further references quoted in those [...] Read more.
This paper reviews the tools available to assess outcomes of treatment in irritable bowel syndrome, especially the effect on abdominal pain. Tools were identified through a wide-ranging scrutiny of PubMed and Google Scholar, together with a review of further references quoted in those publications. It critically considers their development, relevance and reliability. The Irritable Bowel Severity Scoring System (IBS-SSS) was the first simple method of monitoring the progress of the disease and its treatment. It led on to other instruments, such as The Irritable Bowel Syndrome Quality of Life (IBS-QOL). It is easier to read and faster to complete than the IBS-SSS., However, these and other tools were developed for English speaking populations. This review considers the impact of ethnicity and gender, together with the lack of information on the effect of age on the potential validity of these tools in other populations. Issues with the adequacy and appropriateness of translations of such tools are discussed. The overall conclusion is that there are few tools which meet the criteria necessary to place confidence in their validity as appropriate measures of patient outcomes. Full article
(This article belongs to the Special Issue Coeliac Disease 2.0)
9 pages, 397 KiB  
Review
Interventions to Increase Adherence to a Gluten Free Diet in Patients with Coeliac Disease: A Scoping Review
by Humayun Muhammad, Sue Reeves, Sauid Ishaq and Yvonne Jeanes
Gastrointest. Disord. 2020, 2(3), 318-326; https://doi.org/10.3390/gidisord2030029 - 21 Sep 2020
Cited by 5 | Viewed by 4236
Abstract
Coeliac disease is a chronic inflammatory disorder of the small bowel, characterised by permanent intolerance to gluten. The only current and effective treatment for coeliac disease is a gluten free diet [GFD], however this is challenging for patients to adhere to. The review [...] Read more.
Coeliac disease is a chronic inflammatory disorder of the small bowel, characterised by permanent intolerance to gluten. The only current and effective treatment for coeliac disease is a gluten free diet [GFD], however this is challenging for patients to adhere to. The review aims to identify published interventions designed to improve patients’ adherence to a GFD. Ten intervention studies were identified and included within the review; whilst heterogeneous in delivery, all included an educational, behavioural, and practical element. Five interventions significantly improved dietary adherence, these included follow-up appointments, a telephone clinic, an online course, cooking sessions and psychological support. All studies were small and used varied methods to assess adherence. There is a paucity of well-designed interventions to promote dietary adherence, in future more robust methods for ascertaining adherence is needed, we recommend greater inclusion of dietetic assessment and combining more than one method for assessing adherence. Full article
(This article belongs to the Special Issue Coeliac Disease)
►▼ Show Figures

Figure 1

19 pages, 474 KiB  
Review
A Gluten Free Diet in the Management of Epilepsy in People with Coeliac Disease or Gluten Sensitivity
by Zoë Gilbey and Justine Bold
Gastrointest. Disord. 2020, 2(3), 281-299; https://doi.org/10.3390/gidisord2030026 - 8 Sep 2020
Cited by 2 | Viewed by 6128
Abstract
The aim of this review was to assess the effects of a gluten free diet (GFD) in the management of epilepsy in people with coeliac disease (CD) or gluten sensitivity (GS). A systematic approach was used to undertake a literature review. Five electronic [...] Read more.
The aim of this review was to assess the effects of a gluten free diet (GFD) in the management of epilepsy in people with coeliac disease (CD) or gluten sensitivity (GS). A systematic approach was used to undertake a literature review. Five electronic databases (PubMed; Scopus; Google Scholar; Cochrane Epilepsy Group specialised register; Cochrane Register of Controlled Trails (CENTRAL) via the Cochrane Register of Online Trials) were searched using predetermined relevant search terms. In total, 668 articles were identified. Duplicates were removed and predefined inclusion and exclusion criteria were applied, and a PRISMA flow chart was produced. Data was extracted using Covidence software. Twelve studies on Epilepsy and CD involving a total of 70 participants were selected for analysis; narrative synthesis was used owing to the small sample sizes in the selected studies. None of the 12 studies meeting inclusion criteria investigated gluten sensitivity and epilepsy. All the included studies support a link between epilepsy and CD. GFD was effective in 44 out of 70 participants across the studies in terms of a reduction of seizures, reduction of antiepileptic drugs (AEDs) or normalisation of EEG pattern. A total of 44 participants showed a reduction in seizures (across eight studies) and complete cessation of seizures was reported in 22 participants. In general, the earlier the GFD is implemented after the onset of seizures, the better the likelihood of the GFD being successful in supporting control of seizures. Mechanisms linking gluten with epilepsy are not fully understood; possible hypotheses include gluten mediated toxicity, immune-induced cortical damage and malabsorption. Evidence suggests the effectiveness of a GFD in supporting the management of epilepsy in patients with CD, although the quality of evidence is low. There appears to be a growing number of neurologists who are prepared to advocate the use of a GFD. A multidisciplinary approaches and further research are recommended. It could be argued that when balancing potential treatments such as AEDs or surgery, a GFD has a low likelihood of harm. Full article
(This article belongs to the Special Issue Coeliac Disease)
►▼ Show Figures

Figure 1

10 pages, 267 KiB  
Review
Should the Glu Be Ten or Twenty? An Update on the Ongoing Debate on Gluten Safety Limits for Patients with Celiac Disease
by Inna Spector Cohen, Andrew Day and Ron Shaoul
Gastrointest. Disord. 2020, 2(3), 202-211; https://doi.org/10.3390/gidisord2030021 - 22 Jul 2020
Cited by 2 | Viewed by 3018
Abstract
The only currently accepted and recommended treatment for individuals diagnosed with celiac disease (CD) is a strict life-long gluten-free diet (GFD). While the use of the GFD is well-established, strict adherence to diet is not easy to accomplish. In addition, the administration of [...] Read more.
The only currently accepted and recommended treatment for individuals diagnosed with celiac disease (CD) is a strict life-long gluten-free diet (GFD). While the use of the GFD is well-established, strict adherence to diet is not easy to accomplish. In addition, the administration of a GFD may be compromised by inadvertent exposure to small amounts of gluten. International guidelines define a gluten-free product as one containing less than 20 parts per million (ppm), (20 milligrams of gluten per 1 kg of food) gluten. A number of reports have assessed the safe upper limit for gluten exposure for patients with CD, with general consensus that patients with CD should limit their daily intake to less than 50 mg. Full article
(This article belongs to the Special Issue Coeliac Disease)
12 pages, 298 KiB  
Review
An Overview of International Guidelines Focusing on the Long-Term Management of Coeliac Disease
by Sophie W. Hall and Andrew S. Day
Gastrointest. Disord. 2020, 2(2), 152-163; https://doi.org/10.3390/gidisord2020016 - 12 Jun 2020
Cited by 3 | Viewed by 2644
Abstract
Coeliac disease (CD) is an autoimmune disorder characterised by, but not isolated to, intestinal enteropathy in response to exposure to gluten in predisposed individuals. The mainstay of the management of CD is a strict, lifelong gluten free diet (GFD). Although numerous publications have [...] Read more.
Coeliac disease (CD) is an autoimmune disorder characterised by, but not isolated to, intestinal enteropathy in response to exposure to gluten in predisposed individuals. The mainstay of the management of CD is a strict, lifelong gluten free diet (GFD). Although numerous publications have focused on pathways to guide the diagnosis of CD, recommendations for the care of patients after diagnosis are less well established. This manuscript aimed to review the available published guidelines focusing on the ongoing management and follow-up of patients after diagnosis with CD and commencement of a GFD. All available guidelines recommend strict adherence to a GFD with most recommending an annual review by a specialist clinician, focusing on symptoms, adherence and growth. In addition to monitoring micronutrient status, some guidelines suggest monitoring bone mineral density in at-risk groups and screening for other autoimmune disorders. The benefit of multi-disciplinary input was outlined in many guidelines, in particular, the involvement of a specialist dietitian to provide nutritional counselling and support. While the available guidelines provide key messages, they highlight a lack of strong evidence and some inconsistences. Further evidence is required to support high quality, best-practice management strategies that will optimise the outcomes of patients with CD. Full article
(This article belongs to the Special Issue Coeliac Disease)

Other

Jump to: Editorial, Review

4 pages, 222 KiB  
Commentary
The Contribution of Non-Food-Based Exposure to Gluten on the Management of Coeliac Disease
by Sophie W. Hall, Ron Shaoul and Andrew S. Day
Gastrointest. Disord. 2020, 2(2), 140-143; https://doi.org/10.3390/gidisord2020014 - 22 May 2020
Cited by 4 | Viewed by 3312
Abstract
The management of coeliac disease involves the life-long adherence to a strict gluten free diet. There have been concerns about exposure to gluten or other cereal components that are not contained in foods. This manuscript reviews the available literature focused on the potential [...] Read more.
The management of coeliac disease involves the life-long adherence to a strict gluten free diet. There have been concerns about exposure to gluten or other cereal components that are not contained in foods. This manuscript reviews the available literature focused on the potential for exposure to non-food-based gluten and the potential relevance of this to the ongoing management of individuals with coeliac disease. The products of consideration included dental and oral hygiene products, cosmetics and packaging products. Each of these items has been considered, with caution noted in regards to dental products and potential concern about novel packaging applications. Accidental ingestion by younger children of items such as play-dough during play also requires care. In conclusion, there is currently little firm data to guide individuals with coeliac disease, other than caution about specific items. Full article
(This article belongs to the Special Issue Coeliac Disease)
5 pages, 240 KiB  
Commentary
Nonceliac Gluten Sensitivity—A Masquerading IBS or a Real Phenomenon?
by Yoram Elitsur and Deborah Preston
Gastrointest. Disord. 2020, 2(2), 118-122; https://doi.org/10.3390/gidisord2020011 - 2 May 2020
Viewed by 2672
Abstract
The gluten-free diet has become popular among the public. People who are using this diet have reported symptom relief once gluten has been removed from their diet. Nonceliac gluten sensitivity (NCGS) has emerged as a new diagnosis for those patients who have tested [...] Read more.
The gluten-free diet has become popular among the public. People who are using this diet have reported symptom relief once gluten has been removed from their diet. Nonceliac gluten sensitivity (NCGS) has emerged as a new diagnosis for those patients who have tested negative for celiac disease. Although there are no diagnostic markers established for NCGS, its symptomatology ranges from gastrointestinal symptoms to neuropsychiatric symptoms. Indeed, some of these symptoms are also seen in patients with irritable bowel syndrome (IBS), such as abdominal pain, bloating, altered bowel movement, diarrhea, and constipation. It is important to add that unlike celiac disease, NGCS has never been associated with any long-term malignancy. We aim to review the recent clinical data available on this topic and address the overlap symptoms between NCGS and IBS. We concluded that despite the overlap symptoms between both diseases, NCGS is a real clinical phenomenon that awaits its own diagnostic clinical criteria and specific laboratory markers. We suggest that patients with gluten sensitivity who are negative for celiac disease should be considered for NCGS. Full article
(This article belongs to the Special Issue Coeliac Disease)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-8
Back to TopTop